Axial Spondyloarthritis Clinical Trial
Official title:
Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs: Application of Pharmacotherapeutic Conditioning in Clinical Practice.
Verified date | December 2015 |
Source | University Hospital of North Norway |
Contact | n/a |
Is FDA regulated | No |
Health authority | Norway: Norwegian Medicines Agency |
Study type | Interventional |
The following study investigates the role of information/expectancies in the response to
Ibumetin and placebo.
The study is a double-blind randomized controlled trial with crossover, within subjects
repeated measurements. The symptoms are measured by questionnaires. 40 patients will be
included in the study. The administrated drug is Ibumetin 400 mg.
The study does not require patients to meet in the clinic. Patients will be instructed in
how to report pain, tension and nervousness via mobile phone (Checkware AS, Trondheim,
Norway).Three days a week for 12 weeks the patients are instructed to report at 0900 AM, and
thereafter at 0910, 1100, 1300, 1500, 1700, and 1900 hrs each study day. At these times the
patients will receive a sms where they are instructed to immediately rate their pain and
stress level and report back.
Status | Completed |
Enrollment | 8 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have been diagnosed with radiographic Axial Spondyloarthritis, also called Ankylosing Spondylitis, OR - Patients must have been diagnosed with non-radiographic Axial Spondyloarthritis with a positive magnetic resonance (MR). - Patients must have been successfully treated with NSAIDs for at least three months - Patients must be above 20 years old - Patients must satisfy the Norwegian Summary of Product Characteristics (SPC) for Ibumetin 400 mg - All patients must sign a consent form describing that they will receive placebo during the study period. The Informed Consent Form and The Data Release Form must be signed before inclusion in the studies. Exclusion Criteria: - Patients cannot participate in other clinical studies parallel to the current study. Previous study participations must be completed more than one year, prior to participating in the current study. - Patients not satisfying the Norwegian Summary of Product Characteristics (SPC) for Ibumetin 400 mg: - Patients who previously have experienced allergic reactions to NSAIDs - Patients with previous or currant ulcers and/or gastrointestinal conditions - or bleeding - Patients with previous or currant cardiovascular conditions, or have experienced cardiovascular episodes - Patients with previous or currant renal failure - Patients with acetaminophen - or NSAID-induced asthma, urticarial or rhinitic - Patients with previous or current other serious conditions apart from rheumatoid arthritis - Female patients trying to or having trouble getting pregnant cannot participate in the study - Pregnant and/or nursing patients cannot participate in the study - Patients on a treatment plan with Prednisolon - Patients on a treatment plan with substances inflicting with Ibumetin. All substances will be investigated on www.interaksjoner.no |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Norway | University Hospital of Northen Norway | Tromsø |
Lead Sponsor | Collaborator |
---|---|
University Hospital of North Norway | University of Tromso |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in level of pain | up to 12 weeks | No | |
Secondary | Change in level of stress and nervousness | up to 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05031767 -
Remote Monitoring of Axial Spondyloarthritis
|
N/A | |
Completed |
NCT05162937 -
to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis
|
Phase 2 | |
Completed |
NCT03622658 -
Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis
|
Phase 2 | |
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Terminated |
NCT02437162 -
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
|
Phase 3 | |
Enrolling by invitation |
NCT06072859 -
The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)
|
N/A | |
Completed |
NCT02552212 -
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
|
Phase 3 | |
Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
Terminated |
NCT02897115 -
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
|
Phase 4 | |
Completed |
NCT05019547 -
The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
|
||
Recruiting |
NCT03738956 -
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT04679649 -
Physiotherapy of Axial Spondyloarthritis
|
N/A | |
Enrolling by invitation |
NCT02962479 -
Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?
|
N/A | |
Completed |
NCT04485078 -
Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
|
||
Recruiting |
NCT05812157 -
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
|
N/A | |
Completed |
NCT03039088 -
PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
|
||
Completed |
NCT04368494 -
Exercise Therapy in Patients With Axial Spondyloarthritis
|
N/A | |
Completed |
NCT03270501 -
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
|
Phase 3 |